Genomically Basal-Type Tumors Demonstrate Distinct Immune Profiles and Chemosensitivity Across Self-Reported Race Among Patients Enrolled in FLEX Receiving Neoadjuvant Chemotherapy

Authors

• Nicole Stivers
• Nathalie Johnson
• Mehran Habibi
• Marcela Canola
• Ahmed Elkhanany
• Fengting Yan
• Nicole Sookhan
• Jaime Alberty
• Laila Samian
• Sasha Davis
• Eric Brown, Corewell Health East
• Linsey Gold, Corewell Health East

Document Type

Conference Proceeding - Restricted Access

Publication Date

8-2026

Publication Title

Annals of Surgical Oncology

Volume

33

Issue

Suppl 2

First Page

S502

Last Page

S503

Recommended Citation

Stivers N, Johnson N, Habibi M, Canola M, Elkhanany A, Yan F, et al. [Brown E, Gold L]. Genomically basal-type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2026 Aug;33(Suppl 2):S502-S503. doi:10.1245/s10434-026-20020-9

Comments

American Society of Breast Surgeons (ASBrS) Annual meeting, April 29 - May 3, 2026, Seattle, WA

DOI

10.1245/s10434-026-20020-9